dipyridamole has been researched along with Adverse Drug Event in 9 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety of fixed-dose combination aspirin-extended-release (ER) dipyridamole for stroke prevention in patients with ischemic heart disease is reviewed." | 4.86 | Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease. ( Crown, N; Mysak, T, 2010) |
| "Intravenous administration of aminophylline is widely adopted to reverse dipyridamole-related adverse effects (AEs) during stress myocardial perfusion imaging (MPI)." | 1.40 | Experience of low-dose aminophylline use to relieve minor adverse effects of dipyridamole in patients undergoing stress myocardial perfusion imaging. ( Cheng, CY; Hou, CH; Ku, CH; Lin, LF; Shen, DH; Tseng, NC, 2014) |
| "We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)." | 1.36 | Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010) |
| " Evidence of systemic toxicity was observed in animals dosed chronically with pyrimethamine or amiloride, but no skin papillomas were observed in mice treated with amiloride, dipyridamole, or pyrimethamine for 26 weeks." | 1.32 | Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components. ( Lin, KK; Rosenzweig, BA; Sistare, FD; Thompson, KL; Weaver, JL; Zhang, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Lin, LF | 1 |
| Cheng, CY | 1 |
| Hou, CH | 1 |
| Ku, CH | 1 |
| Tseng, NC | 1 |
| Shen, DH | 1 |
| Massalha, S | 1 |
| Reizberg, I | 1 |
| Israel, O | 1 |
| Kapeliovich, M | 1 |
| Sholy, H | 1 |
| Koskosi, A | 1 |
| Keidar, Z | 1 |
| Marai, I | 1 |
| Diedler, J | 1 |
| Ahmed, N | 1 |
| Sykora, M | 1 |
| Uyttenboogaart, M | 1 |
| Overgaard, K | 1 |
| Luijckx, GJ | 1 |
| Soinne, L | 1 |
| Ford, GA | 1 |
| Lees, KR | 1 |
| Wahlgren, N | 1 |
| Ringleb, P | 1 |
| Crown, N | 1 |
| Mysak, T | 1 |
| Sanfiorenzo, C | 1 |
| Pipet, A | 1 |
| Thompson, KL | 1 |
| Rosenzweig, BA | 1 |
| Weaver, JL | 1 |
| Zhang, J | 1 |
| Lin, KK | 1 |
| Sistare, FD | 1 |
2 reviews available for dipyridamole and Adverse Drug Event
| Article | Year |
|---|---|
Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Drug-Related Side | 2010 |
[Exacerbations of asthma--precipitating factors: drugs].
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Contraindications; Dip | 2011 |
7 other studies available for dipyridamole and Adverse Drug Event
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Experience of low-dose aminophylline use to relieve minor adverse effects of dipyridamole in patients undergoing stress myocardial perfusion imaging.
Topics: Adult; Aged; Aged, 80 and over; Aminophylline; Cardiotonic Agents; Comorbidity; Coronary Artery Dise | 2014 |
Conduction abnormalities during dipyridamole stress testing.
Topics: Atrioventricular Block; Bradycardia; Causality; Comorbidity; Coronary Artery Disease; Dipyridamole; | 2017 |
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh | 2010 |
Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components.
Topics: Acetone; Administration, Topical; Amiloride; Animal Testing Alternatives; Animals; Carcinogenicity T | 2003 |